DETAILED ACTION
Disposition of Claims
Claims 1-14 were pending. Claim 6 has been cancelled. Amendments to claims 1-3, 7, 9-11, and 14 are acknowledged and entered. Claims 1-5 and 7-14 will be examined on their merits.
Examiner’s Note
Applicant is encouraged to utilize the new web-based Automated Interview Request (AIR) tool for submitting interview requests; more information can be found at https://www.uspto.gov/patent/laws-and-regulations/interview-practice.
All paragraph numbers, unless otherwise noted, correspond to the USPGPub of this application, US20240050549A1, Pub. 02/15/2024. Amendments to the specification presented on 08/05/2026 are acknowledged and entered.
Optional Authorization to Initiate Electronic Communications
The authorization to correspond with the Examiner via electronic mail (e-mail) presented on 08/05/2026 is acknowledged and entered.
Response to Arguments
Applicant's arguments filed 08/05/2026 regarding the previous Office action dated 03/05/2026 have been fully considered. If they have been found to be persuasive, the objection/rejection has been withdrawn below. Likewise, if a rejection/objection has not been recited, said rejection/objection has been withdrawn. If the arguments have not been found to be persuasive, or if there are arguments presented over art that has been utilized in withdrawn rejections but utilized in new rejections, the arguments will be addressed fully with the objection/rejection below.
Specification – Sequence Disclosures
(Objection withdrawn.) The objection to the specification for sequence disclosures is withdrawn in light of the amendments to the specification.
Specification - Drawings
(Objection maintained – petition decision forthcoming.) The rationale behind this objection was set forth in a previous Office action. It is noted that a petition was filed on 08/05/2026 to accept color drawings. That petition is still under review at the time of this Office action.
Claim Rejections - 35 USC § 112(b); Second Paragraph
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
(Rejection withdrawn.) The rejection of Claim 1 and dependent claims 2-6 thereof under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is withdrawn in light of the amendments to the claims.
(Rejection withdrawn.) The rejection of Claim 2 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is withdrawn in light of the amendments to the claim.
(Rejection withdrawn.) The rejection of Claims 6, 7, and 14, and dependent claims 8-13 thereof under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is withdrawn in light of the amendments to the claims and the reconsideration of the rejection.
(Rejection withdrawn.) The rejection of Claims 9-11 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is withdrawn in light of the amendments to the claims.
(New rejection – necessitated by amendment.) Claims 1, 7, and 14 and dependent claims 2-5 and 8-13 thereof are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Independent claims 1, 7, and 14 recite an attenuated, recombinant Ranavirus strain that “has been deleted of pathogenesis genes and a viral envelope.” The term “pathogenesis genes” in these claims is a relative term which renders the claim indefinite. The term “pathogenesis genes” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The wording of the claim does not identify which genes must be deleted from the recombinant virus, and whether all genes associated with “pathogenesis” must be deleted or only a subset of these genes must be deleted. Although the specification discusses non-essential, putative pathogenesis genes, and identifies the 40L locus of Ambystoma tigrinum virus (ATV) as a target for deletion, it does not clearly establish the boundaries of the claimed class of “pathogenesis genes” or the deletions required to satisfy the limitation, especially with respect to the more broadly claimed Ranaviruses in independent claims 7 and 14.
Further, the limitation of “deleted of… a viral envelope” is indefinite because a viral envelope is a structural component of a viral particle rather than a genomic sequence. It is therefore unclear whether the claim requires deletion of genes encoding viral envelope-associated proteins, deletion of all genes necessary for formation of the viral envelope, or the physical absence of an envelope from the recombinant viral particles. The specification discusses deletion of non-essential genes and purification of intracellular virions lacking an envelope, but does not clearly establish which modification is required by the claims.
Accordingly, the structural and functional boundaries of the claimed virus strains is unclear and cannot be reasonably ascertained.
Since a skilled artisan would not be reasonably apprised as to the metes and bounds of the claimed invention, instant Claims 1, 7, and 14 are rejected on the grounds of being indefinite. Claim(s) 2-5 and 8-13 are also rejected since they depend from claims 1, 7, or 14, but do not remedy these deficiencies of claims 1, 7, or 14.
Claim Rejections - 35 USC § 112(a); First Paragraph
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
(Rejection withdrawn.) The rejection of Claims 3 and 6-14 under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph, is withdrawn in light of the ATV being deposited under the terms of the Budapest Treaty (see affidavit filed 08/05/2026).
(New rejection – necessitated by amendment.) Claims 1-5 and 7-14 are rejected under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
The written description requirement is separate and distinct from the enablement requirement. To satisfy the written description requirement, the specification must reasonably convey to one skilled in the relevant art that the inventor had possession of the claimed invention as of the filing date. Possession may be shown by a description of the complete structure of the claimed invention, a representative number of species falling within the scope of a claimed genus, or relevant identifying characteristics sufficient to show that the inventor had possession of the claimed subject matter.
Claims 1-5 and 7-14 recite expression systems and methods employing said expression systems, wherein the expression system is an attenuated, recombinant Ranavirus strains having at least one expression element, wherein the recombinant strains have been deleted of pathogenesis genes and a viral envelope. The method claims broadly encompass recombinant strains derived from any member of the genus Ranavirus, while the product claims limit the Ranavirus to Ambystoma tigrinum virus (ATV). The specification describes recombinant ATV constructs, particularly ATVΔ40L constructs containing expression elements for a green fluorescent protein fused to a neomycin resistance gene (GNR). The specification describes the generation of recombinant ATV strains having a deletion at the 40L locus, including ATVΔ40L-CMV-GNR and ATVΔ40L-SEL-GNR, and demonstrates expression of the GNR construct in mammalian cells and mouse respiratory tissues (¶[0031][0033-0035][0041-0043][0049]).
However, the scope of the claims is not limited to the embodiments described in the specification.
With respect to claims 1-5, the independent claim is limited to an attenuated, recombinant ATV strain that has been deleted of pathogenesis genes and a viral envelope. Although ¶[0021-0022] generally recite the deletion of pathogenesis genes and a viral envelope, the specification does not adequately describe the structural modifications encompassed by the amended limitation. Specifically, ¶[0006] describes “deleting non-essential genes” and separately “purifying intracellular virions that lack an envelope.” These disclosures describe deletion of genetic material and purification of non-enveloped viral particles as distinct operations, rather than deletion of genes responsible for producing a viral envelope. Further, although ¶[0022] identifies four loci or genes that may be deleted, the specification provides experimental data for only one locus, specifically the ATV 40L locus described at ¶[0049]. The specification does not identify the remaining pathogenesis associated genes or otherwise describe the structural modifications encompassed by the broader limitation requiring deletion of pathogenesis genes.
The specification describes recombinant ATV constructs having a deletion at the 40L locus. However, claims 1-5 are not limited to that genetic modification and, to the extent that the amended language requires genetic elimination of the viral envelope, encompass additional ATV constructs that are not adequately described in the specification. The specification does not identify genes responsible for viral envelope formation whose deletion would produce the claimed recombinant ATV strains, describe representative constructs having such deletions, or otherwise demonstrate possession of genetically modified ATV strains incapable of producing a viral envelope. The general disclosure of deleting pathogenesis genes and purifying non-enveloped virions does not reasonably convey possession of the broader group of genetically modified ATV strains incapable of producing a viral envelope. The general disclosure of deleting pathogenesis genes and purifying non-enveloped virions does not reasonably convey possession of the broader group of genetically modified ATV constructs encompassed by this interpretation of claim 1.
The method claims broadly encompass attenuated, recombinant strains derived from other members of the genus Ranavirus, including strains having different genomic organizations and pathogenesis-associated genes. The specification expressly recognizes that ATV differs from other members of the genus Ranavirus, including differences in genome organization and host range. Specifically, ¶[0030] states that “ATV has a unique overall gene order as compared to other ranaviruses.” The specification also describes differences in the number of encoded proteins among ranaviruses, while ¶[0033] identifies the temperature-dependent replication and host-restricted characteristics of ATV. These disclosures do not establish that the genetic modifications or biological characteristics of the disclosed recombinant ATV constructs are representative of other members of the claimed genus.
The specification does not describe a sufficient number of species representative of the claimed scope. Although table 2 identifies numerous members of the genus Ranavirus and provides their genomic accession numbers, the specification does not describe corresponding attenuated, recombinant strains of those viruses having the recited deletions and expression elements. Further, while ¶[0038] describes a general procedure for generating a recombinant Ranavirus, the working examples are directed to ATV. The specification also does not describe structural features common to the claimed genus which would allow one skilled in the art to recognize which additional species fall within the scope of the claimed invention. Instead, one skilled in the art would be required to select additional ranavirus strains not described in the specification and determine which genetic modifications would produce the recited attenuated, recombinant ranaviruses.
The claimed recombinant Ranaviruses are defined, at least in part, by the recited function of attenuated and the recited deletion of pathogenesis gens and a viral envelope. Although ¶[0021-0022] generally describe recombinant viruses having these modifications, the specification does not establish a correlation between the disclosed structural features of ATV and the recited characteristics sufficient to identify additional recombinant strains falling within the scope of the claims. In particular, ¶[0022] identifies four loci or genes that may be deleted, but provides data for only one locus. The specification does not identify corresponding pathogenesis genes or deletion loci across the broader genus Ranavirus, or establish that the disclosed ATV modifications are representative of the genetic modifications required in other Ranavirus species. The disclosure of the desired function (e.g. attenuation and recombinant expression characteristics), without a sufficient description of the claimed genus, does not demonstrate possession of the full scope of the claims.
The specification only describes recombinant ATV constructs having a deletion of the 40L locus and containing mammalian expression elements, as discussed in ¶[0046-0049]. However, the claims are not limited to those constructs, as the claims also encompass constructs that are derived from other ranavirus species, having different pathogenesis gene deletions or modifications associated with the viral envelope. The specification does not describe representative examples across that scope or identify structural features sufficient to show possession of the broader group of constructs. The disclosure of recombinant ATV constructs does not reasonably convey possession of the substantially broader genus of recombinant Ranavirus strains encompassed by the claims.
Further, with respect to claim 14, the specification describes a proposed method of using recombinant ATV to deliver antigens to mammalian respiratory tissues for generating antiviral airway immunity (¶[0027-0036]). However, claim 14 broadly encompasses methods employing recombinant strains of any member of the genus Ranavirus to reduce the occurrence of mammalian respiratory disease. The experimental results demonstrate possession of the GNR reporter construct in mammalian respiratory cells and mouse tissues, but do not demonstrate reduced occurrence of respiratory disease or protective immunity following administration of the recombinant viruses. The specification does not describe representative therapeutic embodiments across that scope or otherwise demonstrate possession of methods employing the broader group of recombinant ranavirus strains for reducing mammalian respiratory disease. The disclosure of recombinant protein expression using ATV does not reasonably convey possession of the broader therapeutic method encompassed by claim 14.
Accordingly, the disclosure does not reasonably convey to one skilled in the art that the inventor had possession of the full scope of the subject matter recited in claims 1-5 and 7-14 at the time the application was filed.
(New rejection – necessitated by amendment.) Claims 1-5 and 7-14 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for certain attenuated, recombinant ATV embodiments, particularly those having a deletion at the ATV 40L locus, does not reasonably provide enablement for the broader group of recombinant Ranaviruses or ATV strains having the recited pathogenesis gene and viral envelope deletions, or for methods employing attenuated Ranaviruses comprising said deletions. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.
The legal considerations that govern enablement determinations pertaining to undue experimentation have been set forth in In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). The factors to be considered include: (1) the breadth of the claims; (2) the nature of the invention; (3) the state of the prior art; (4) the level of one of ordinary skill; (5) the level of predictability in the art; (6) the amount of direction provided by the inventor; (7) the existence of working examples; and (8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure. The factors are considered as a whole in determining whether any necessary experimentation would have been undue.
Nature of the invention and breadth of the claims. The claimed invention is directed to recombinant, attenuated ATV comprising deletions of pathogenesis genes and viral envelope, and to methods of delivering antigens to mammals using attenuated, recombinant Ranaviruses comprising deletions of pathogenesis genes and viral envelope, wherein the recombinant Ranaviruses have at least one expression element. The specification describes recombinant ATV constructs, particularly ATVΔ40L-CMV-GNR and ATVΔ40L-SEL-GNR, in which the 40L locus has been deleted and replaced with an expression construct encoding GFP fused to neomycin resistance (GNR). The specification demonstrates expression of GNR in mammalian cells, including differentiated human bronchial epithelial cells and mouse respiratory tissues, without productive viral replication (¶[0033-0054]).
However, the claims are not limited to the limited disclosed ATV Δ40L embodiments. The claims also encompass additional deletions in ATV genes related to pathogenesis, and additional deletions in ATV related to the viral envelope. The claims additionally encompass methods employing recombinant strains derived from other members of the genus Ranavirus, including viruses having different genomic organizations and biological properties. The claimed scope therefore extends beyond the embodiments described in the specification.
State of the prior art and predictability of the art. At the time the application was filed, it was known that members of the genus Ranavirus exhibited genetic diversity and differences in host range. See for instance Sriwanayos et. al. (Sriwanayos P, et. al. FACETS, 2020, 5(1): 963-979.), especially the phylogenomic analysis and comparative genomic results. The instant specification further acknowledges these differences at ¶[0030], which states that “ATV has a unique overall gene order as compared to other ranaviruses.” At this same paragraph, the specification also identifies differences in host range and genome size among members of the genus. The specification further describes ATV as thermally limited to replication below 28 deg C and host restricted compared to other members of the genus (¶[0033]). These properties are relevant to the disclosed use of recombinant ATV for expressing foreign proteins in mammalian cells without producing infectious viral particles.
With respect to full genomic analysis of ranaviruses, the art remained relatively unexplored at the time of filing with many ranaviruses, even with ATV. Robert et. al. (Robert J, et. al. Viruses. 2016 Jul 6;8(7):187.) noted that “[d]espite their growing economic and ecological significance, ranaviruses have not been as extensively studied as other families of large double-stranded DNA (dsDNA) viruses (e.g., Poxviridae and Herpesviridae), and their mechanisms of replication, infection, and pathogenesis are still poorly understood.” Aron et. al. (Aron MM, et. al. Virus Res. 2016 Jun 2;217:107-14. Epub 2016 Mar 26.; CITED ART OF RECORD IN PARENT; hereafter “Aron”) developed a simplified, reliable and standardized process to identify essential and non-essential genes in ATV by homologous recombination, but it remained that all genes important for pathogenesis remained to be identified for ATV and other ranaviruses.
The prior art and instant disclosure do not establish that the particular genetic modifications responsible for attenuation, the genes responsible for pathogenesis and/or formation of the viral membrane, or the temperature-dependent replication characteristics of ATV, are conserved among the claimed genus. Accordingly, the results obtained using the 40L deleted recombinant ATV would not have reasonably established that the broader claimed scope could be practiced without further experimentation.
Level of skill in the art. One skilled in the art would have been familiar with viral genetic engineering techniques, including homologous recombination, preparation of recombinant expression cassettes, and selection of genetically modified viruses. Methods for evaluating viral replication and recombinant protein expression were also known. However, the existence of known methods for preparing and testing candidate embodiments does not establish that one skilled in the art would have known, without further experimentation, which additional gene deletions in which Ranaviruses would satisfy the claimed limitations, especially for ranaviruses capable of delivering antigens to mammalian cells. The knowledge required to perform these techniques does not eliminate the need to determine whether the resulting viruses would possess the biological properties necessary to practice the claimed methods.
Working examples. The specification provides working examples directed to recombinant ATV constructs generated by modification of the ATV 40L locus. Specifically, ¶[0049] describes the generation of ATVΔ40L-CMV-GNR and ATVΔ40L-SEL-GNR, while ¶[0041-0043] and ¶[0054] describe their evaluation in mammalian cells and mice. The specification does not provide working examples directed to other pathogenesis genes of ATV being deleted, any envelope gene deletions, or any other type or strain of Ranavirus species having the claimed deletions in pathogenesis and envelope genes. The disclosed examples therefore do not establish enablement across the full scope of the claims.
Guidance in the specification. The specification provides guidance regarding preparation of recombinant ATV constructs using homologous recombination and selection of recombinant viruses having deletions at a target open reading frame (¶[0038][0046-0049]). At ¶[0022] the specification also describes four loci or genes that may be deleted, although experimental data are provided for only one locus.
However, the specification does not provide sufficient guidance regarding the identification of additional pathogenesis genes in ATV, the envelope genes in ATV, or corresponding pathogenesis or envelope genes in other ranavirus species or which deletions would produce attenuated recombinant strains suitable for the claimed methods. In particular, the specification does not explain whether deletion of genes corresponding to the ATV 40L locus would produce comparable attenuation in other ranaviruses, or whether additional genetic modifications would be required. The specification also does not establish how the recited deletion of a viral envelope is to be accomplished across the claimed genus or whether such modification would preserve the ability of the recombinant viruses to enter mammalian cells and express the incorporated genetic material. Although ¶[0038] generally describes a method of generating recombinant Ranavirus, the disclosure does not establish that application of this procedure to other members of the genus would produce recombinant strains having the recited attenuation and expression characteristics. The specification therefore provides insufficient direction for practicing the full scope of the claimed methods.
Quantity of experimentation necessary. To practice the full scope of the claims, one skilled in the art would need to identify not only additional pathogenesis genes in ATV, but also envelope genes in ATV, as well as identify pathogenesis and envelope genes in other Ranaviruses. Additionally, one would have to determine which of these genes can be deleted and produce the attenuation while retaining the properties necessary for mammalian cell entry and expression, and evaluate the resulting recombinant strains for their ability to deliver the recited antigens.
Such experimentation would not merely involve the routine application of known methods to embodiments reasonably expected to work. Instead, one skilled in the art would need to prepare and test additional recombinant ATV and Ranavirus embodiments to determine whether they satisfy the ability to produce an attenuated virus, especially one that can still deliver heterologous payloads to mammalian cells for the treatment of respiratory disease. Given the differences among ranavirus species and the limited guidance provided by the ATV examples, this experimentation would require more than routine verification of predictable results.
Further, claim 14 specifically requires delivery of antigens to a mammal to reduce ethe occurrence of mammalian respiratory disease. The specification describes a proposed application of recombinant ATV for generating antiviral airway immunity (¶[0027][0032-0036]). However, the working examples demonstrate expression of a GNR reporter construct and preliminary safety observations rather than protective immunity or a reduction in the occurrence of respiratory disease (¶[0035][0054]). The specification does not provide sufficient guidance regarding which antigens would be effective for reducing the occurrence of mammalian respiratory disease when delivered using the broadly claimed recombinant ranaviruses, or the administration conditions necessary to achieve the recited result.
Although the individual methods used to prepare and test candidate embodiments may have been known in the art, the relevant inquiry is not whether one skilled in the art could perform the required assays. The relevant inquiry is whether the specification provides sufficient guidance to identify and practice the embodiments falling within the full scope of the claims without undue experimentation. Here, one skilled in the art would need to prepare and test additional ranavirus mutants to determine which embodiments satisfy the claimed attenuation, or the claimed ability to deliver heterologous payloads.
Amgen. The Supreme Court has explained that a specification need not describe with particularity how to make and use every embodiment within a claimed class. However, the disclosure must enable one skilled in the art to make and use the full scope of the claimed invention. A reasonable amount of experimentation may be permissible depending on the nature of the invention and the underlying art. Amgen Inc. v. Sanofi, 598 U.S. 594, 610-13 (2023).
In the instantly claimed invention, the specification describes recombinant ATV constructs having a deletion at the 40L locus and containing mammalian expression elements, but the claims also encompass additional ATV with additional mutations, and additional Ranaviruses with mutations in any pathogenesis and envelope genes. The specification does not identify a general quality or provide sufficient guidance that would allow one skilled in the art to practice that broader scope without undue experimentation.
Conclusion. For the reasons discussed above, the specification does not enable one skilled in the art to make and/or use the full scope of the invention recited in the claims without undue experimentation.
Claim Interpretation
The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art.
Claim 1 is drawn to a mammalian expression system comprising an attenuated, recombinant ranavirus strain that has at least one expression element, wherein the attenuated, recombinant ranavirus strain is Ambystoma tigrinum virus that has been deleted of pathogenesis genes and a viral envelope and further comprising at least one mammalian transcriptional and translational enhancement element that are incorporated into the ranavirus strain.
Further limitations on the mammalian expression system of claim 1 are wherein the at least one mammalian transcriptional and translational enhancement element expresses a green fluorescent protein (GFP) fused to a neomycin resistance gene (NR) in non-permissive cells in vitro, in differentiated primary human cells ex vivo, and in mouse lungs and trachea in vivo without viral replication (claim 2); wherein the at least one mammalian transcriptional and translational enhancement element comprises ATVΔ40L-SEL-GNR, ATV∆40L-GFP or a combination thereof (claim 3); wherein the expression element expresses at least two proteins (claim 4); and wherein the expression element expresses at least two proteins fused together (claim 5).
Claim 7 is drawn to a method of delivering antigens to a mammal, comprising: providing a mammalian expression system comprising an attenuated, recombinant ranavirus strain that has at least one expression element, wherein the ranavirus strain has been deleted of pathogenesis genes and a viral envelope; and administering to the mammal a therapeutic amount of the attenuated, recombinant ranavirus strain that has at least one expression element.
Further limitations on the method of claim 7 are wherein the attenuated, recombinant ranavirus strain is Ambystoma tigrinum virus (claim 8); further comprising at least one mammalian transcriptional and translational enhancement element that are incorporated into the ranavirus strain (claim 9), wherein the at least one mammalian transcriptional and translational enhancement element delivers GNR in non-permissive cells in vitro, in differentiated primary human cells ex vivo, and in mouse lungs and trachea in vivo without viral replication (claim 10), wherein the at least one mammalian transcriptional and translational enhancement element comprises ATVΔ40L-SEL-GNR, ATV∆40L-GFP or a combination thereof (claim 11); wherein the expression element expresses at least two proteins (claim 12); wherein the expression element expresses at least two proteins fused together (claim 13).
Claim 14 is drawn to a method of delivering antigens to a mammal to reduce the occurrence of mammalian respiratory disease, comprising: providing a mammalian expression system comprising an attenuated, recombinant ranavirus strain that has at least one expression element; wherein the ranavirus strain has been deleted of pathogenesis genes and a viral envelope; and administering to the mammal a therapeutic amount of the attenuated, recombinant ranavirus strain that has at least one expression element.
Claim Rejections - 35 USC § 102
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
NB: The prior art rejections are withdrawn at this time in light of the amendments to the claims which provide substantial ambiguity concerning the scope of the amended independent claims. Specifically, it is unclear which genetic modifications are encompassed by the recited deletion of pathogenesis genes and a viral envelope, as set forth supra in the 35 USC 112b rejection. The interpretations set forth in that rejection materially affect the scope of the claimed subject matter, the relevance of the 35 USC 112a rejections, and the applicability of the prior art. Accordingly, further consideration of the prior art will be undertaken upon clarification of the claimed limitations.
(Rejection withdrawn.) The rejection of Claims 1 and 4 under 35 U.S.C. 102(a)(1) as being anticipated by Jancovich et. al. (Jancovich JK, et. al. J Virol. 2011 May;85(10):5061-9. Epub 2011 Mar 9; CITED ART OF RECORD IN PARENT; hereafter “Jancovich”) is withdrawn in light of the amendments to the claims.
(Rejection withdrawn.) The rejection of Claims 1-6 under 35 U.S.C. 102(a1) as being anticipated by Aron et. al. (Aron MM, et. al. Virus Res. 2016 Jun 2;217:107-14. Epub 2016 Mar 26.; CITED ART OF RECORD IN PARENT; hereafter “Aron”) is withdrawn in light of the amendments to the claims.
Claim Rejections - 35 USC § 103
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
(Rejection withdrawn.) The rejection of Claims 7-14 under 35 U.S.C. 103 as being unpatentable over Aron as applied to claims 1-6 above and Jancovich as applied to claims 1 and 4 above, and further in view of Boyce (US6238914B1, Iss. 05/29/2001; hereafter “Boyce”) is withdrawn in light of the amendments to the claims.
Conclusion
No claims are allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to RACHEL B GILL whose telephone number is (571)272-3129. The examiner can normally be reached on M to F 8:00 AM to 5:00 PM Eastern.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Allen can be reached on (571) 270-3497. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/RACHEL B GILL/
Primary Examiner, Art Unit 1671